Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3089
Source ID: NCT02352974
Associated Drug: Gad-Alum
Title: GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
Acronym: DIAGNODE
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02352974/results
Conditions: Diabetes Mellitus, Type 1
Interventions: DRUG: GAD-Alum|DRUG: Vitamin D
Outcome Measures: Primary: Number of Subjects With Injection Site Reactions Month 1, Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching), Month 1|Number of Subjects With Injection Site Reactions Month 2, Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching), Month 2|Number of Subjects With Injection Site Reactions Month 3, Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching), Month 3|Number of Subjects With Injection Site Reactions Month 32, Reactions of the injection site (Erythema, Oedema, Haematoma, Tenderness, Pain, Itching), Month 32, extension period | Secondary: Mean Change in C-peptide AUC (Area Under the Curve) (Mean 120min) Value, Month 15, Change from baseline to month 15 in C-peptide AUC (Area Under the Curve) (mean 120min) value AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L\*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration, Baseline to month 15 at 0, 30, 60, 90, 120 minutes post-dose|Mean Change in C-peptide AUC(Mean 120min) Value, Month 30, Change from baseline to month 30 in C-peptide AUC(mean 120min) value AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L\*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration, Baseline to month 30 at 0, 30, 60, 90, 120 minutes post-dose|Mean Change in C-peptide AUC(Mean 120min) Value, Month 43, Change from baseline to month 43 in C-peptide AUC(mean 120min) value AUC (mean 120min) (nmol/L) is the C-peptide AUC during an MMTT (nmol/L\*minutes) divided by the duration of the MMTT (minutes) i.e. C-peptide weighted average concentration, Baseline to month 43, extension period at 0, 30, 60, 90, 120 minutes post-dose|Mean Change in C-peptide 90-minute Value, Month 15, Change from baseline to month 15 in C-peptide 90-minute value, Baseline to month 15|Mean Change in C-peptide 90-minute Value, Month 30, Change from baseline to month 30 in C-peptide 90-minute value, Baseline to month 30|Mean Change in C-peptide 90-minute Value, Month 43, Change from baseline to month 43 in C-peptide 90-minute value, Baseline to month 43, extension period|Mean Change in Fasting C-peptide Value, Month 15, Change from baseline to month 15 in fasting C-peptide value, Baseline to month 15|Mean Change in Fasting C-peptide Value, Month 30, Change from baseline to month 30 in fasting C-peptide value, Baseline to month 30|Mean Change in Fasting C-peptide Value, Month 43, Change from baseline to month 43 in fasting C-peptide value, Baseline to month 43, extension period|Mean Change in HbA1c, Month 15, Change from baseline to month 15 in HbA1c, Baseline to month 15|Mean Change in HbA1c, Month 30, Change from baseline to month 30 in HbA1c, Baseline to month 30|Mean Change in HbA1c, Month 43, Change from baseline to month 43 in HbA1c, Baseline to month 43, extension period|External Insulin Dose, Baseline, External insulin dose at baseline, Baseline|External Insulin Dose, Month 15, External insulin dose at month 15, Month 15|External Insulin Dose, Month 30, External insulin dose at month 30, Month 30|External Insulin Dose, Month 43, External insulin dose at month 43, Month 43, extension period|Mean IDAA1c Values, Baseline, Insulin dose-adjusted HbA1c (IDAA1c), Baseline|Mean IDAA1c Values, Month 15, Insulin dose-adjusted HbA1c (IDAA1c), Month 15|Mean IDAA1c Values, Month 30, Insulin dose-adjusted HbA1c (IDAA1c), Month 30|Mean IDAA1c Values, Month 43, Insulin dose-adjusted HbA1c (IDAA1c), Month 43, extension period
Sponsor/Collaborators: Sponsor: Johnny Ludvigsson | Collaborators: Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB
Gender: ALL
Age: CHILD, ADULT
Phases: PHASE1
Enrollment: 12
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2015-01
Completion Date: 2019-10
Results First Posted: 2020-04-27
Last Update Posted: 2020-04-27
Locations: Linköping University, Linköping, Sweden
URL: https://clinicaltrials.gov/show/NCT02352974